Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Scotland Fails To Recommend Orkambi But 'New Medicines Fund' Should Enable Access

Executive Summary

The Scottish Medicines Consortium (SMC) on May 9 published advice mirroring that of its neighbor NICE failing to recommend the use of Vertex's Orkambi on the UK's NHS for the treatment of cystic fibrosis. This comes despite positive reimbursement decisions in other European countries. However, Scotland's New Medicines Fund should ensure there is a route available for patients to access the medicine, Vertex believes.

You may also be interested in...



Another No For Vertex As Scotland Rejects Offer For Orkambi And Symkevi

The Scottish Medicines Consortium has issues over the price Vertex Pharmaceuticals is asking for its cystic fibrosis drugs, and like NICE in England it has rejected the products for use on the National Health Service.

'No Surprise' Says Vertex As NICE Fails To Recommend Orkambi In CF

Vertex Pharmaceuticals Inc. says it is "not surprised" that NICE has issued draft guidance not recommending Orkambi (lumacaftor/ivacaftor) for use on the NHS in England.

UK Reimbursement Decisions Focus Mostly On Cancer

The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.

Topics

UsernamePublicRestriction

Register

SC065137

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel